Although data for adjuvant pertuzumab is currently lacking, it is recommended by National Comprehensive Cancer Center Network guidelines as a component of adjuvant therapy [107] for high-risk HER2-positive breast cancer based on improved survival when used in metastatic HER2-postive breast cancer [108], and improved pathologic complete response when used in locally advanced breast cancer [109]. This evidence concerns the gene ERBB2 and breast carcinoma.